The potential role of por*28 and cyp1a2*f genetic variations and lifestyle factors on clozapine and n-desmethyl clozapine plasma levels in schizophrenia patients.

The findings of the present study highlight the importance of both genetic and non-genetic factors (smoking and caffeine consumption) for the individualization of the CLZ treatment. In addition to that, it suggests that the added utility of not only the CLZ metabolizing enzymes but also POR, which is crucial for proper CYP activity, to guide CLZ dosing might be useful for clinical decision-making.